Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Title
Intervention Indication Therapeutic Area Year Actions
Lisocabtagene maraleucel for relapsed or refractory, aggressive B-cell non-Hodgkin Lymphoma – second line Lisocabtagene maraleucel (Liso-cel; JCAR017) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma Lisocabtagene maraleucel (Liso-cel; JCAR017) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Loncastuximab Tesirine for relapsed or refractory diffuse large B-cell lymphoma – third line Loncastuximab Tesirine (ADCT-402; Lonca; Zylonta) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Luspatercept for myelodysplastic syndromes (MDS) associated anaemia Luspatercept (ACE-536; Reblozyl) Anaemia due to myelodysplastic syndromes (MDS) Haematological Cancer and Lymphomas , Haematology 2018 View  |  Download
Magrolimab in addition to azacitidine for myelodysplastic syndromes - First-line Azacitidine (Vidaza; CC-486) , Magrolimab (Hu5F9-G4) Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2021 View  |  Download
Mechlorethamine gel for mycosis fungoides in cutaneous T-cell lymphoma Mechlorethamine (Ledaga; Valchlor) Cutaneous T-cell lymphoma (CTCL) Haematological Cancer and Lymphomas 2019 View  |  Download
Melphalan flufenamide in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Melphalan flufenamide hydrochloride (Ygalo; Mel-flufen; J-1) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Momelotinib for the treatment of symptomatic and anaemic myelofibrosis Momelotinib Anaemic myelofibrosis Haematological Cancer and Lymphomas , Haematology 2022 View  |  Download
Mosunetuzumab for relapsed or refractory B-cell follicular lymphoma – third-line and greater Mosunetuzumab (BTCT4465A) Follicular lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
1 2 8 9 10 11 12 14 15
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications